| Revenue growth | 27.9% YoY in FY26; Q4 grew 15.7% YoY. |
|---|---|
| Margins | FY26 EBITDA margin 34.6%; expected to return to 37-38% levels. |
| Order book | 700 metric tons initial commercial orders for battery materials. |
| Demand visibility | Strong traction in LFP value chain; 42 customers in qualification pipeline. |
| Management confidence | High, citing strategic milestones in battery materials and nutrition platforms. |
Growth
FY26 Revenue grew 27.9% to ₹642.3cr; PAT increased 25.7% to ₹174.3cr. Specialty ingredients revenue surged 62% YoY.
Outlook
Commissioning 25,000 MT Phase 1 battery materials by April 2027; targeted revenue potential ₹1,600-1,800cr at 100k MT peak capacity.
Risks
Volatile raw material prices (phosphoric acid), LPG supply disruptions, and high working capital days (213 days).
Earnings Call filed with BSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,164.90
- Market cap
- ₹13,157 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.0×Sector 50.4×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Investor Presentation: Key Takeaways
Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).
Sudeep Pharma Q1 FY27 Results: Net Profit ₹40.6 Cr, Up 29.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹40.6 Cr · +29.7% YoY
Sudeep Pharma Earnings Call Transcript: Key Takeaways
Sudeep Pharma reported strong H1 FY26 growth, despite Q2 US tariff headwinds causing temporary revenue slippage. The transition towards high-margin specialty ingredients and battery materials via the 'Sam' vertical defines their strategic pivot.
Sudeep Pharma Earnings Call: Key Takeaways
Sudeep Pharma reported record FY26 revenue of ₹642.3cr, driven by the listing, the NSS acquisition, and expansion into battery materials.
Sudeep Pharma Q4 FY26 Results: Net Profit ₹48.5 Cr, Up 9.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹182.3 Cr (+15.7% YoY) and net profit of ₹48.5 Cr (+9.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹48.5 Cr · +9.7% YoY